This large-scale analysis looked at over 124,000 adults with psoriasis to see if certain treatments affected the risk of developing psoriatic arthritis. The study followed these patients for over 778,000 person-years to track changes in their joint health.
The findings show that patients using biologic therapies had a 46% lower risk of developing psoriatic arthritis compared to those on non-biologic treatments. Specifically, IL-23 and IL-17 inhibitors were associated with lower risks than tumor necrosis factor inhibitors. The data also showed that IL-23 inhibitors were linked to a lower risk than IL-17 inhibitors.
Because this was an observational study, researchers cannot say for certain that the medications caused the lower risk. Other factors could influence the results. These findings are helpful for understanding how different treatments might affect long-term joint health, but you should talk to your doctor to decide which treatment is best for your specific needs.
